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Histamine and its receptors were first described as part of immune and gastrointestinal systems, but their presence
in the central nervous system and importance in behavior are gaining more attention. The histaminergic system
modulates different processes including wakefulness, feeding, and learning and memory consolidation. Histamine
receptors (H1R, H2R, H3R, and H4R) belong to the rhodopsin-like family of G protein-coupled receptors, present
constitutive activity, and are subjected to inverse agonist action. The involvement of the histaminergic system in
brain disorders, such as Alzheimer’s disease, schizophrenia, sleep disorders, drug dependence, and Parkinson’s
disease, is largely studied. Data obtained from preclinical studies point antagonists of histamine receptors as promising
alternatives to treat brain disorders. Thus, clinical trials are currently ongoing to assess the effects of these drugs on
humans. This review summarizes the role of histaminergic system in brain disorders, as well as the effects of different
histamine antagonists on animal models and humans.
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Described for the first time in 1910 as a promoter of con-
traction of smooth muscles and vasodilatation, histamine
acts as a transmitter in the central nervous system (CNS)
and modulates several other physiological processes, like
gastrointestinal and circulatory functions, innate and
acquired immunity, cell proliferation and hematopoiesis.
Today, its presence in the CNS and importance in behav-
ior are largely studied [1,2].
Histamine synthesis and release are regulated by H3R,
an autoreceptor present in the somata and axon terminals
of histaminergic neurons. Histamine is synthesized from
L-histidine by histidine decarboxylase, and it is metabo-
lized by diamine oxidase and histamine N-methyltransfer-
ase (HNMT) [3]. Other receptors, such as muscarinic,* Correspondence: diego@baronio.com.br
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unless otherwise stated.opioid, and galanin, regulate histamine release in specific
brain regions [4-6].
Histaminergic neurons are located in the tuberomamil-
lary nucleus (TMN) of the hypothalamus, with widespread
projections innervating most brain areas. Postmortem
studies indicate that the number of histaminergic neurons
in humans is about 64,000 [7]. There are four histamine
receptors, all part of the rhodopsin-like family of G pro-
tein-coupled receptors (GPCR). Through these receptors,
histamine regulates several basic body functions, such as
wakefulness, feeding, and learning and memory [8-10].Histamine receptors
In 1966, Ash and Schild discovered the H1R while study-
ing the effect of antihistamine drugs in the rat uterus and
stomach [11]. After that, three other receptors (H2R,
H3R, and H4R) were identified. The four receptors are
part of the GPCR superfamily, and they all present consti-
tutive activity [12-15].
The GPCR superfamily modulates several physiological
processes and is divided into families and subfamilies,
and single subtypes can present different isoforms. Thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that these receptors could be activated without the pres-
ence of an agonist [16]. Binding of a ligand to a receptor
may initiate activity (agonist with positive intrinsic activ-
ity) or prevent the effect of an agonist (antagonist with
zero intrinsic activity). While the agonists stabilize the
receptor in active conformation, the inverse agonists
stabilize the receptor in inactive conformation and thus
reduce the activity (negative intrinsic activity) [17]. Two
isoforms of the H3R are highly constitutively active: the
wild type and an isoform with a deletion in the third
intracellular loop [18].
From the four histaminergic receptors, H1R is the
main target of most of the approved drugs [19] and is
found in different tissues and cells, including the smooth
muscle, brain, and lymphocytes [20,21]. This receptor is
the only member of the family of histamine receptors,
of which a co-crystal was obtained, by using the first-
generation antagonist doxepin (PDB ID 3RZE) [22].
As for all members of this family, this receptor comprises
seven transmembrane helices (TMH), three intracellular
loops, and three extracellular loops. The binding pocket
of H1R has a conserved hydrophobic nature, which
contributes to the low selectivity of doxepin and the
first-generation of H1R antagonists, and is associated to
an anion-binding region which has been related to the
binding of second-generation H1R antagonists. Such
crystallographic structure can be used as a model in
further development of new blockers as well as in the
understanding of the activation-inactivation mechanisms
of this receptor family at molecular level. The signal
transduction of H1R includes activation of phospholipase
C, which promotes the inositol triphosphate-dependent
release of Ca2+ from intracellular stores and diacylglyc-
erol-sensitive activation of protein kinase C [2,23].
H1R is involved in the modulation of important
processes and mice lacking this receptor present different
impairments, for example, in spatial memory and in sleep-
wake characteristics [24,25]. Injection of a H1R agonist in
the median preoptic nucleus, a region involved in basal
thermoregulation, induces persistent hyperthermia [26].
Other study with mutant mice lacking H1R suggested a
role for this receptor in somatic and visceral pain percep-
tions. These animals showed fewer nociceptive responses
to the hot-plate, tail-flick, tail-pressure, paw-withdrawal,
formalin, capsaicin, and abdominal constriction tests [27].
The pioneer study by Ash and Schild indicated, at that
time, the existence of at least two classes of histamine
receptors, since the antagonists utilized in that experiment
did not stop gastric acid secretion [11]. Later, compounds
that blocked the gastric acid secretion in guinea pig,
named H2R antagonists, were developed by Black and
colleagues [28]. Like H1R, H2R presents typical GPCR re-
ceptor characteristics. Its activation stimulates adenylylcyclase leading to cyclic adenosine monophosphate
(cAMP) production, a second messenger that has dif-
ferent roles in the cell [29]. The role of H2R in the CNS
is not fully understood, but basic research showed that
it is related to the processes of learning and memory,
motor control, and thermoregulation [30,31]. In some
areas of the brain, colocalization of H1R and H2R suggests
synergistic interactions between these two receptors [32].
In an animal model of multiple sclerosis, it was demon-
strated that both H1R and H2R are propathogenic, medi-
ating immune deviation and blood brain barrier (BBB)
disruption [33].
Mainly found in the brain, H3R regulates food intake,
memory, acetylcholine (ACh) release, and consolidation
of fear memories [34,35]. Activation of H3R inhibits cAMP
synthesis and activates MAP kinases and the AKT/GSK3β
axis [36-38]. When activated, the receptor inhibits cell
firing and decreases the release of histamine by histamin-
ergic neurons, as well as inhibits secretion of norepineph-
rine, serotonin, and other neurotransmitters [13,39,40].
Recently, several alterations were reported in mice lacking
H3R. They presented enhanced histaminergic neurotrans-
mission, which led to changes in the mice phenotype,
indicating a possible metabolic disorder as a consequence.
The sleep was also altered, in a condition similar to sleep
restriction in humans, which matches with obesity ten-
dency presented by these animals [41].
Almost 15 years ago, H4R was the last histamine recep-
tor to be identified. It is mainly related with immune func-
tions, but its presence in the brain is known, as well as in
the bone marrow, peripheral blood, spleen, thymus, small
intestine, colon, heart, and lung [42-44]. It modulates dif-
ferent processes such as dendritic cells activity, interleukins
release, and likely regulation of BBB permeability [45-47].
In humans, the presence of H4R messenger RNA
(mRNA) was detected in the spinal cord, hippocampus,
cerebral cortex, thalamus, and amygdala, with levels in
the spinal cord overcoming the levels found in the
spleen and liver. The authors also verified the presence
of the receptor in the dorsal root ganglia, which might
indicate a nociceptive role for the receptor. In rats, the
cerebellum and hypothalamus presented the highest
amounts of H4R mRNA [48].
Histaminergic system and brain disorders
Alterations in the histaminergic system have been
reported in several brain disorders and might have a
significant role in their pathophysiology [49-52]. Con-
sidering this, it is not surprising that pharmacological
studies are in development to explore the potential-
ities of histamine antagonists/inverse agonists in the
treatment of these disorders. Table 1 shows the uses
and outcomes of histamine receptors antagonists cited
in this review.
Table 1 Histamine receptors antagonists: therapeutic applications and outcomes
Receptor Drug Disorder Study Outcome Reference
H1R Chlorpheniramine Model of stress by immobilization/sleep
disturb
Preclinical Reduction in REM sleep. [53]
Dimebon AD Clinical No significant improvement in a phase III trial. [54]
Doxepin Insomnia Clinical Improvements in sleep maintenance and duration
in a 4-week outpatient trial of elderly adults.
[55,56]
H2R Dimebon AD Clinical No significant improvement in a phase III trial. [54]
Famotidine Autism Clinical Attenuated symptoms like irritability, hyperactivity
and atypical pattern of eye contact in children
with autism.
[57]
SCH Clinical Reduced scores in BPRS, CGI, and SANS. [58,59]
H3R GSK239512 AD Clinical Failed on improving executive function/working
memory in a randomized, double-blind,
placebo-controlled.
[60]
ABT-288 AD Clinical No significant improvements in a randomized study. [61]
SCH Clinical Failed on providing cognitive improvements
to patients.
[62]
JNJ-10181457 Model of AD Preclinical Reversed cognitive deficits induced by scopolamine
and normalized ACh neurotransmission.
[63]
Pitolisant Narcolepsy Clinical Reduced excessive daytime sleepiness [64]
ABT-239 Model of SCH Preclinical Attenuated cognitive deficits caused by ketamine
and MK-801.
[50]
A-431404 Model of SCH Preclinical Attenuated cognitive deficits caused by ketamine
and MK-801.
[50]
JNJ-31001074 ADHD Clinical No significant improvements in adult patients. [65]
Betahistine SCH Clinical Reduced weight gain by patients with SCH
treated with olanzapine.
[66]
JNJ-39220675 Model of alcoholism Preclinical Reduced intake of alcohol after a period of
abstinence.
[67]
Thioperamide Model of SCH Preclinical Enhancement of prepulse inhibition. [68]
Model of PD Preclinical Decreased hyperactivity. [69]
GSK189254 Model of neuropathic pain Preclinical Antinociceptive effect. [70,71]
GSK334429 Model of neuropathic pain Preclinical Antinociceptive effect. [71]
SAR110894 Model of SCH Preclinical Normalized impaired social behavior. [72]
Ciproxifan Model of SCH Preclinical Enhancement of prepulse inhibition. [68]
Model of AD Preclinical Improvements in hyperactivity and memory deficits. [73]
H4R JNJ7777120 Model of neuropathic pain Preclinical Antinociceptive effect. [74,75]
ZPL3893787 Tested in healthy volunteers. Potential
treatment for asthma, allergic rhinitis,
pain, and other inflammatory diseases.
Clinical Completed phase I trial. Safe and well tolerated. [76]
UR63325 Allergic rhinitis Clinical Currently on phase II clinical trial. No data available. [76]
KD1157 Tested in healthy volunteers. Potential
treatment for allergic rhinitis.
Clinical Safe and well tolerated. [76]
JNJ38518168 Asthma Clinical Currently on phase II clinical trial. No data available. [76]
JNJ39758979 Asthma Clinical Completed phase II clinical trial. No data available. [76]
Baronio et al. Annals of General Psychiatry 2014, 13:34 Page 3 of 10
http://www.annals-general-psychiatry.com/content/13/1/34Alzheimer’s disease
Alzheimer’s disease (AD) affects approximately 5.4
million US citizens and the costs with patients, including
health care, long-term care, and hospitalization, make it
a social problem [77]. Even though there is conflictinginformation about the role of histaminergic system in
AD, abnormalities have been reported. A postmortem
study showed reduced histamine content in the hypo-
thalamus, hippocampus, and temporal cortex of patients
with AD [7]. Other report showed 57% less histaminergic
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increased prefrontal cortex expression of H3R. Despite the
severe cell loss, it is suggested that histamine production
is not affected, since the levels of histidine decarb-
oxylase mRNA are unaltered [78]. On the other hand,
Kim and colleagues reported decreased levels of the
histamine-releasing factor in the temporal cortex of
patients with AD, as well as in the temporal cortex,
thalamus, and caudate nucleus of patients with Down
syndrome, indicating low levels of brain histamine in
these disorders [79].
The development of new treatments for AD is a perman-
ent issue. Positive results after a double-blind, placebo-
controlled, phase II trial led to great expectations about the
possibility of dimebon becoming a drug to treat AD, with
patients displaying significant improvement over baseline
for Alzheimer’s disease Assessment Scale [80]. Dimebon
acts as an antagonist of H1R and H2R, and it also binds to
adrenergic, serotonergic, and dopaminergic receptors.
Unfortunately, a phase III trial with 598 patients found
no significant improvement in patients with AD treated
with this drug [54].
In a preliminary investigation GSK239512, an H3R
antagonist/inverse agonist was tested in order to assess
its tolerability and cognitive effects in patients with AD.
The patients displayed no abnormalities in hematology,
clinical chemistry, urinalysis parameters, and cardiovascu-
lar parameters. Enhancements in cognition were assessed,
with subjects showing positive effects on attention and
memory [60]. In a larger trial, GSK239512 was considered
safe and able to improve episodic memory in patients with
AD, but it failed on improving executive function/working
memory [81]. Other H3R antagonists, such as ABT-288,
have also failed in clinical trials [61].
On the other hand, interesting findings were reported
when ciproxifan, also H3R antagonist, was tested in a
transgenic mouse model of AD. Improvements in some
impairments featured in this disorder, such as hyperactiv-
ity and memory deficits were detected after administration
of this drug [73]. This was also performed with rats that
received scopolamine, a non-selective muscarinic antag-
onist that induces cognitive impairments and reduces
ACh release, similar to what is found in AD. Treatment
with JNJ-10181457, a selective non-imidazole H3R an-
tagonist, not only reversed cognitive deficits induced by
scopolamine but also normalized ACh neurotransmis-
sion [63].
Sleep disturbs
Histamine has an important role in the control of sleep-
wake regulation. Studying histaminergic TMN neurons
of cats in different states, Vanni-Mercier reported a slow,
but regular spontaneous firing during wake state, dimin-
ished in slow-wave sleep and absent firing during rapid eyemovement [82]. Histidine decarboxylase gene knockout
mice showed that impaired histamine synthesis prevents
remaining in a wake state [83]. In agreement with that,
patients with narcolepsy and idiopathic hypersomnia
present reduced level of histamine in the cerebrospinal
fluid (CSF) [84].
In rats, inverse agonism of H1R with ketotifen increased
non-rapid eye movement (REM) sleep and decreased REM
sleep, coinciding with significant prolongation of sleep
duration and longer slow-wave sleep, suggesting a restful
sleep [85]. In a model of stress by immobilization, the per-
centage for REM sleep is increased but is abolished in rats
after administration of an H1R antagonist/inverse agonist,
chlorpheniramine. The reduction of REM sleep caused
by chlorpheniramine administration was significant even
when compared to non-stressed control rats [53].
Recently, doxepin efficacy and tolerability were tested
in elderly patients with chronic primary insomnia. During
4 weeks, 130 patients received 6 mg of doxepin nightly
while 124 patients received placebo. According to patient
self-report instruments and clinician ratings, the treatment
was well tolerated and led to significant improvements in
sleep maintenance and duration [55]. Another recent trial
investigated the effects of doxepin in Parkinson’s dis-
ease (PD) patients with insomnia. Non-pharmacological
treatment, 10 mg of doxepin nightly and placebo were
compared during 6 weeks. Sleep variables were improved
in the doxepin-treated and in the non-pharmacological
groups, with the doxepin treatment appearing to have
more substantial clinical benefits. The authors do not
claim for a superiority of pharmacological treatment and
point to advantages of the non-pharmacological, such as
absence of pharmacological side effects and potential
long-lasting benefits after treatment [56].
Beneficial effects of histamine antagonists are also seen
in narcoleptic patients that received 40 mg of tripolisant
daily for a week. The H3R inverse agonist was consid-
ered safe, and no serious adverse effects were reported
during the study. Despite the small population studied,
the authors highlight that after treatment, patients pre-
sented a reduction in somnolence, compared to baseline,
equivalent to results after several months of modafinil
treatment [64]. The same drug was tested in four teen-
agers with narcolepsy-catalepsy that presented severe
daytime sleepiness and were refractory to available treat-
ments. Pitolisant decreased sleepiness with few minor ad-
verse effects [86]. In positron emission tomography (PET)
study, after calculating H3R occupancy, it was verified that
AZD5213 is able to exert its wake-promoting action dur-
ing daytime and does not disrupt sleep during the night.
This is consequence of its pharmacokinetics that allows
circadian fluctuations of H3R occupancy. Thus, patients
would benefit from the procognitive effects of H3R
without presenting sleep disruption [87].
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Schizophrenia (SCH) is a heterogeneous disorder with
strong genetic influence, highly prevalent, affecting 1.1%
of the US population [88]. The involvement of the dopa-
minergic system in the pathophysiology of this disorder
is well known, with antipsychotics acting mainly on D2
receptor [89]. However, a role for the histaminergic system
has been proposed, and several novel pharmaceutical tar-
gets are acting on both dopaminergic and histaminergic
systems [90]. Iwabuchi and colleagues evaluated the distri-
bution of H1R in the brains of medicated schizophrenic
patients and normal human subjects but found no dis-
crepancy between the groups. They also calculated the
binding potential of the receptor by PET and doxepin,
a radioligand for H1R, and noted that the value of
the binding potential was particularly lower in the frontal
and prefrontal cortices and the cingulate gyrus of patients
with SCH [51]. Analyzing postmortem brain samples of
patients with SCH, Jin and colleagues found that medi-
cated patients displayed lower H3R binding level in the
hippocampal CA2 region. The prefrontal cortices of the
same patients presented higher H3R radioligand binding
than the controls’, and this alteration was correlated with
psychotic symptoms, indicating a role of H3R in modula-
tion of cognition [91]. Recently, it was reported that a
H4R polymorphism may be a molecular marker for the
prediction of risperidone efficacy [92].
In the 1990s, the effect of an H2R antagonist, commonly
used in the treatment of peptic ulcer, was evaluated in
patients with SCH. During 3 weeks, in an open-label trial,
ten patients received 20 mg twice a day of famotidine
without interrupting their treatment with conventional
antipsychotics. Famotidine led to significant reduction in
the scores of Brief Psychiatric Rating Scale (BPRS) and
Clinical Global Impression (CGI), suggesting its adminis-
tration as a useful alternative for SCH treatment [58].
Later, another open-label trial was performed with 18
patients receiving 100 mg of famotidine daily, during
3 weeks. Significant improvements were found after mea-
surements with BPRS, CGI, and the Schedule for the
Assessment of Negative Symptoms (SANS) [93]. Recently,
a randomized clinical trial for famotidine was performed
with 30 patients with SCH, 16 patients received 100 mg of
famotidine twice daily and 14 received placebo. Famo-
tidine caused no significant adverse effects, and it led to
great reduction in symptoms for both the Positive and
Negative Syndrome Scale and CGI [59].
In an animal model of SCH, impaired prepulse inhib-
ition was enhanced in the DBA/2 mouse after inverse
agonism of H3R with thioperamide and ciproxifan [68].
The use of ABT-239 and A-431404, also non-imidazole
H3R antagonists, attenuated cognitive deficits caused
by ketamine and MK-801 in rats, showing better results
than antipsychotics, olanzapine, and risperidone, also usedin the study, to treat these deficits [50]. Antagonists/in-
verse agonists of H3R have also shown to possess antioxi-
dant activity, which could supplement antioxidant needs
of SCH [94]. Despite the promising results obtained in
preclinical models, when ABT-288 was tested in a rando-
mized trial, it failed in providing cognitive improvements
to patients with SCH. In addition, this treatment was
associated with sleep disruption [62]. Other reports of
disappointing results regarding the use of H3R antagonists
in the treatment of disorders, such as attention-deficit
hyperactivity disorder (ADHD), raise questions about the
practicability of these drugs on the translational level [65].
Weight gain is a common side effect associated with
some antipsychotic agents that may affect adherence to
treatment [95]. Recently, the use of H3R antagonists was
investigated as an alternative to attenuate weight gain
caused by olanzapine in patients with SCH. A combin-
ation of reboxetine, a selective norepinephrine reuptake
inhibitor, and betahistine, a potent antagonist of H3R was
tested in a double-blind placebo-controlled study. The
combination of 4 mg of reboxetine and 48 mg of betahis-
tine was given daily, for 6 weeks, to 29 patients treated
with olanzapine. Placebo was given to 14 patients also
treated with olanzapine. The combination of reboxetine/
betahistine resulted in significantly less weight gain com-
pared to the placebo group [66].
Addiction
It is known that alterations in different neurotransmission
systems, such as glutamate system dysfunction, interaction
between serotonin transporter and serotonin receptor 1B
genes polymorphisms, and dopamine-beta hydroxylase
polymorphism have been associated with drug depend-
ence [96-98]. The histaminergic system might as well be
involved in modulation of behaviors associated with
addiction. A polymorphism of HNMT gene was found in
abundance in alcoholics from two different populations.
Higher levels of the enzyme HNMT may lead to decreased
levels of histamine and the low levels of this amine could
be linked to an anxious behavior, since the patients with
the polymorphism also displayed higher harm avoidance,
a dimensional rating of anxious personality. Vulnerability
to alcohol dependence is commonly associated with anx-
ious behavior. In animals, it was demonstrated that stimu-
lation of H1R modulates an anxiogenic effect, while H2R
does the opposite. The authors speculate that the carriers
of the polymorphism may present low levels of histamine
in the amygdaloid nuclei, a structure associated with
anxiety and with high density of H2R [99].
Nuutinen and colleagues showed that when alcohol
solution and plain water were offered to mice lacking H3R
in a two-bottle choice procedure, these animals would
drink less alcohol solution, compared to control animals.
Also, in animals without the H3R, alcohol did not generate
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ation [100]. Similar results were obtained when rats were
treated with JNJ-39220675. After 3 days of deprivation,
rats were exposed to alcohol again 15 min after receiving
a subcutaneous injection of JNJ-39220675. The animals
displayed reduced intake of alcohol after a period of
abstinence, just when the urge for drinking is enhanced
[67]. Clinical studies should be performed to assess poten-
tial benefits and risks of these drugs to treat alcoholic
patients.
Parkinson’s disease
Reports of higher levels of histamine in the blood of
patients with PD and in postmortem studies indicate a
role for the histaminergic system on this disease [101].
The histaminergic innervation in the middle portion of
substantia nigra pars compacta and reticulata was in-
creased in the brains of patients with PD, which may be
due to a compensatory event caused by deficiency of
dopamine or a putative fiber growth inhibitory factor
[102]. In postmortem brain samples of patients with PD,
histamine concentrations were significantly increased in
the putamen, substantia nigra pars compacta, internal
globus pallidus, and external globus pallidus when com-
pared to age-matched controls. This is probably a conse-
quence of reduced metabolism, since the concentrations
of tele-methylhistamine, a histamine metabolite, were
unchanged [103]. Other study reported a significant de-
crease in the expression of H3R mRNA and a significant
increase of HNMT mRNA expression, both in the sub-
stantia nigra of patients with PD. The disease duration
(years between diagnosis and death) was negatively cor-
related with HNMT mRNA expression [104].
In a rat model of PD, obtained by brain lesion after
bilateral icv administration of 6-hydroxydopamine, high
levels of histamine were identified. Increased locomotor
activity caused by the lesion and stereotyped behavior
promoted by injection of apomorphine, were attenu-
ated by administration of thioperamide, a H3R antag-
onist. Antagonists of H1R and H2R were also tested,
but the symptoms caused by the lesion were not
attenuated [69].
Pain
The histaminergic system has a role in nociception, with
histaminergic neurons projecting to the dorsal raphe
nucleus and dorsal horn of the spinal cord. The H3R
antagonists GSK189254 and GSK334429 demonstrated
to be promising therapies for the treatment of neuropa-
thic pain, since animals treated with these drugs pre-
sented a decrease in paw withdrawal threshold in the
chronic constriction injury and varicella-zoster virus
models [70]. In addition, GSK189254 produced anti-
nociceptive effects in the model of monoiodoacetateinduced osteoarthritic pain and in a spinal nerve ligation
model of neuropathic pain [71].
Antinociceptive properties of H4R antagonists were
also detected. JNJ7777120 was tested in four different
strains of mice in order to verify its efficacy in a model
of croton oil-induced ear inflammation. Reduction in ear
edema and significant anti-inflammatory effects were
detected in the animals treated with this drug [74]. In
other study, after repeated administration, JNJ7777120
demonstrated an anti-hyperalgesic action in a model of
neuropathic pain. It is not clear how this effect is pro-
duced, although JNJ7777120 possesses anti-inflammatory
properties, it is also possible that a central effect is pro-
duced due to its capacity to cross the BBB [75]. Clinical
studies are currently ongoing in order to evaluate the
therapeutic potential of H4R antagonist in other inflam-
matory diseases, due to the involvement of H4R in im-
mune regulatory functions, including chemotaxis and
cytokine secretion [76].
Perspectives
Over the last years, the role of histaminergic system has
been studied in the pathophysiology of different brain
disorders. Progress in this field of study has been made,
making it possible to investigate different pharmacological
approaches in order to treat or ameliorate symptoms.
Autism, a neurodevelopmental disorder, affects 1 in 68
children in the US and has not a clear etiology or specific
biomarkers [105]. Literature presents scarce data about
the histaminergic system in autism (Table 2), but the
use of an H2R antagonist has been already proposed
and tested in patients. Symptoms like irritability, hyper-
activity, and atypical pattern of eye contact were attenu-
ated after treatment with famotidine [57,106].
There is evidence that H3R is downregulated in Fragile
X syndrome patients, a condition that is strongly associ-
ated with autism [111]. In addition, animals exposed to
phencyclidine (PCP) develop behavioral impairments,
including low interest in social novelty, which is a fea-
ture present also in autism. In this experiment, animals
exposed to PCP spent 3.5 less time investigating a novel
subject than the control group. The administration of a
H3R antagonist/inverse agonist, SAR110894, normalized
this impairment [72]. Recent data points to an involve-
ment of the histaminergic system in the pathophysiology
of Tourette’s syndrome, a condition common among
patients with autism. A premature termination codon
(W317X) in the histidine decarboxylase gene was de-
tected in patients, implying that diminished histaminer-
gic neurotransmission could be related to the outcomes
of this syndrome [114].
Since it is likely that the histaminergic system may
play a role in SCH and Tourette’s syndrome, disorders
that have substantial symptomatic overlap with autism,
Table 2 Studies involving autism and histamine
Year Author Number of patients Number of controls Main results
1972 Neville et al. 7 - Elevated plasma histidine and low skin histidase levels [107].
1979 Kotsopoulos and Kutty 1 - Patient with autism presented histidine blood levels seven
times higher than the upper normal values [108].
1988 Launay et al. 22 22 Histamine levels in urine and whole blood or plasma of patients
with autism did not differ from age- and sex-matched controls [109].
1999 Rossi et al. 25 - Niaprazine (H1R antagonist) showed a positive effect on hyperkinesias,
unstable attention, resistance to change and frustration, mild anxiety
signs, hetero-aggressiveness, and sleep disorders [110].
2001 Linday et al. 9 - Behavioral improvement in children treated with Famotidine
(H2R antagonist) [57].
2010 Rosales-Reynoso et al. 10 10 Downregulation of H3R in patients with Fragile X syndrome, subjects
that usually meet diagnostic criteria for autism [111].
2012 Ming et al. 48 53 Reduced urinary levels of histidine and other amino acids [112].
2013 Naushad et al. 138 138 When compared to normal controls, autistic children showed elevated
levels of histidine (58 +/− 15 vs. 45 +/− 21 micromol/L) [113].
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characterize this system in autism. The animal model
of autism based on prenatal exposure to valproic acid
shows neuroanatomical, behavioral, and biochemical
alterations that recapitulates the core characteristics
of autism [115], which makes it a reliable tool for
studying a likely involvement of the histaminergic
system in this disorder.
Concluding remarks
Initially described as part of immune and gastrointestinal
systems, the presence of histamine and its four described
receptors in the CNS have been related to normal and/
or abnormal behavior. As a result, a growing amount of
information regarding the relationship between histamine
and brain is continuously arising from both experimental
and clinical fields of research.
Based on preclinical data, different antagonists from
histamine receptors have been considered promising
therapies for brain disorders. On the other hand, more
clinical studies are still required to verify practicability of
these drugs. We believe that in-depth investigation in-
volving the histaminergic system and its potential thera-
peutic targets in other disorders, such as autism, should
be performed. Efforts in both preclinical and clinical
research will lead to reaching clinically useful and safe
treatments.
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